Spanyolország - spanyol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

tecnimede espana industria farmaceutica s.a. - sitagliptina hidrocloruro monohidrato; metformina hidrocloruro - comprimido recubierto con pelÍcula - 50 mg/1.000 mg - sitagliptina hidrocloruro monohidrato 50 mg; metformina hidrocloruro 1000 mg - metformina y sitagliptina

Spanyolország - spanyol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

kern pharma s.l. - sitagliptina hidrocloruro monohidrato; metformina hidrocloruro - comprimido recubierto con pelÍcula - 50 mg/850 mg - sitagliptina hidrocloruro monohidrato 50 mg; metformina hidrocloruro 850 mg - metformina y sitagliptina

Spanyolország - spanyol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

kern pharma s.l. - sitagliptina hidrocloruro monohidrato; metformina hidrocloruro - comprimido recubierto con pelÍcula - 50 mg/1.000 mg - sitagliptina hidrocloruro monohidrato 50 mg; metformina hidrocloruro 1000 mg - metformina y sitagliptina

Spanyolország - spanyol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios normon s.a. - sitagliptina hidrocloruro; metformina hidrocloruro - comprimido recubierto con pelÍcula - 50 mg/1.000 mg - sitagliptina hidrocloruro 50 mg; metformina hidrocloruro 1000 mg - metformina y sitagliptina

Európai Unió - spanyol - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, tipo 2 - drogas usadas en diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Európai Unió - spanyol - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, tipo 2 - drogas usadas en diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Spanyolország - spanyol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

vegal farmacéutica, s.l. - sitagliptina malato - excipientes: croscarmelosa sodica - fÁrmacos hipoglucemiantes excluyendo insulinas - inhibidores de la 4 peptidasa (dpp- 4 peptidasa) - sitagliptina

Spanyolország - spanyol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

vegal farmacéutica, s.l. - sitagliptina malato - excipientes: croscarmelosa sodica - fÁrmacos hipoglucemiantes excluyendo insulinas - inhibidores de la 4 peptidasa (dpp- 4 peptidasa) - sitagliptina

Spanyolország - spanyol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

vegal farmacéutica, s.l. - sitagliptina malato - excipientes: croscarmelosa sodica - fÁrmacos hipoglucemiantes excluyendo insulinas - inhibidores de la 4 peptidasa (dpp- 4 peptidasa) - sitagliptina

Spanyolország - spanyol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ratiopharm españa, s.a. - sitagliptina malato - excipientes: croscarmelosa sodica - fÁrmacos hipoglucemiantes excluyendo insulinas - inhibidores de la 4 peptidasa (dpp- 4 peptidasa) - sitagliptina